Side-by-side comparison of AI visibility scores, market position, and capabilities
ZOE is a health science company using large-scale nutritional studies (PREDICT), microbiome sequencing, and AI to deliver personalized nutrition programs; co-founded by scientist Tim Spector and Christopher Gardner; raised $115M+ total;
ZOE is a health science and consumer technology company headquartered in London, United Kingdom, co-founded by Professor Tim Spector (King's College London epidemiologist and author), Jonathan Wolf, and others. The company emerged from the PREDICT studies — the world's largest nutritional science research program, which enrolled over 1,000 participants to study how different individuals respond to the same foods based on their gut microbiome, blood fat response, blood sugar response, sleep, and exercise patterns. The research established that personalized nutrition — rather than one-size-fits-all dietary guidelines — is scientifically grounded, as the same meal can produce dramatically different metabolic responses in different people.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.